23:35 , Mar 2, 2018 |  BC Extra  |  Clinical News

Nektar gains on updated response data for NKTR-214

Nektar Therapeutics (NASDAQ:NKTR) added $18.32 (22%) to $102.87 on Friday after President and CEO Howard Robin said that two additional renal cell carcinoma (RCC) patients who previously achieved stable disease have converted to responders in...
23:25 , Mar 2, 2018 |  BioCentury  |  Product Development

Clever pegylation pay off

Nektar Therapeutics’ clever pegylation strategy allowed it to finesse the PK and dial down the toxicity of IL-2, turning a validated but problematic immuno-oncology mechanism into a viable candidate. The approach snagged a record-breaking deal...
00:08 , Feb 17, 2018 |  BC Extra  |  Financial News

Alkermes hits high following IL-2 deal

Alkermes plc (NASDAQ:ALKS) hit a 52-week high of $71.22 on Friday on the heels of Wednesday's multibillion dollar deal between Nektar Therapeutics (NASDAQ:NKTR) and Bristol-Myers Squibb Co. (NYSE:BMY) involving NKTR-214. A note from Jefferies analyst...
07:00 , Jun 20, 2016 |  BC Week In Review  |  Clinical News

ALKS 4230: Phase I started

Alkermes began a dose-escalation, dose-expansion Phase I trial to evaluate IV ALKS 4230 in patients who are refractory or intolerant to established therapies. Alkermes plc (NASDAQ:ALKS), Dublin, Ireland   Product: ALKS 4230 (formerly RDB...
07:00 , Aug 19, 2013 |  BioCentury  |  Strategy

Delivering on NMEs

With the unveiling of three new preclinical programs, Alkermes plc is fulfilling ambitions first stated in 2011 to evolve from partnering drug delivery technology to discovering and developing its own in-house products, including its first...
07:00 , Jul 22, 2013 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Biogen Idec Inc. (NASDAQ:BIIB) was up $7.15 to $230.27 on Friday after FDA accepted a BLA and EMA accepted an MAA for Plegridy peginterferon beta-1a (BIIB017) to treat relapsing forms of multiple sclerosis (MS)....
00:53 , Jul 18, 2013 |  BC Extra  |  Company News

Alkermes showcases three new programs

Alkermes plc (NASDAQ:ALKS) unveiled three new preclinical programs at its R&D day on Wednesday: small molecule prodrugs of monomethyl fumarate (MMF) for multiple sclerosis (MS); ALK 7106, an opioid modulator for pain; and RDB 1419,...